Meabco Inc. is a drug development company based in Chicago, IL, aiming to advance BP-C2 as a drug candidate for radioprotection/radiomitigation. Its parent company, Meabco A/S, with offices in Denmark, Russia, Norway, and the United States, focuses on breakthrough therapies in cancer treatment and radioprotection. Meabco's technology platform is based on BP-Cx-1, a patented complex of lignin-derived polyphenols, which can be conjugated with different agents to produce functionally different pharmaceuticals. BP-C1 (BP-Cx-1 complexed with platinum) is an oncology drug that has been studied in multiple Phase 1 and 2 clinical trials and is being developed for late stage cancers. BP-C2 (BP-Cx-1 complexed with molybdenum) is a preclinical stage asset that is being developed as a radioprotective and radiomitigative agent with applications in oncology and public health preparedness.
View Top Employees from Meabco A/S| Website | http://www.meabco.com |
| Revenue | $6 million |
| Employees | 1 (1 on RocketReach) |
| Address | 875 N Michigan Ave John Hancock Ctr, Ste 3950, Chicago, Illinois 60611, US |
| Phone | (312) 239-6322 |
| Industry | Manufacturing General, Manufacturing |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies |
Looking for a particular Meabco A/S employee's phone or email?
Meabco A/S Questions
The Meabco A/S annual revenue was $6 million in 2024.
Sergey Pigarev is the CTO of Meabco A/S.
1 people are employed at Meabco A/S.
Meabco A/S is based in Chicago, Illinois.
The NAICS codes for Meabco A/S are [32, 32541, 325, 3254].
The SIC codes for Meabco A/S are [28, 283].
Top Meabco A/S Employees
